The Efficacy of Famotidine in Improvement of Outcomes in Hospitalized COVID-19 Patients: A Phase III Randomized Clinical Trial

Samimagham, Hamid Reza; Hassani Azad, Mehdi; Arabi, Mohsen; Hooshyar, Dariush; Abbasi, Mohammad Amin; Haddad, Maryam; KazemiJahromi, Mitra

doi:10.52547/rabms.8.2.75

Volume 8, Issue 2 (5-2022) Journal of Research in Applied and Basic Medical Sciences 2022, 8(2): 75-82 | Back to browse issues page

‎ 10.52547/rabms.8.2.75

Mendeley

Zotero

RefWorks

Samimagham H R, Hassani Azad M, Arabi M, Hooshyar D, Abbasi M A, Haddad M et al . The Efficacy of Famotidine in Improvement of Outcomes in Hospitalized COVID-19 Patients: A Phase III Randomized Clinical Trial. Journal of Research in Applied and Basic Medical Sciences 2022; 8 (2) :75-82
URL: http://ijrabms.umsu.ac.ir/article-1-183-en.html

The Efficacy of Famotidine in Improvement of Outcomes in Hospitalized COVID-19 Patients: A Phase III Randomized Clinical Trial

Hamid Reza Samimagham

, Mehdi Hassani Azad

, Mohsen Arabi

, Dariush Hooshyar

, Mohammad Amin Abbasi

, Maryam Haddad

, Mitra KazemiJahromi ^*

Endocrinology and Metablism Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran , mitra.kazemijahromi@gmail.com

Abstract: (1639 Views)

Background & Aims: As the first randomized clinical trial, this study evaluated the effect of Famotidine on the improvement of outcomes of hospitalized patients with COVID-19.
Materials & Methods: This phase III randomized clinical trial which was designed with two parallel arms, is a placebo-controlled, single-blind, and concealed allocation study, and recruited 20 patients (10 of them received Famotidine as treatment group and 10 received Placebo as control group). Oral Famotidine 160 mg four times a day was given to the COVID-19 patients until the discharge day or for a maximum of 14 days. Patients’ temperature, respiration rate, oxygen saturation, lung infiltration, lactate dehydrogenase (LDH) level, and complete blood count (CBC) were measured at the baseline (before the intervention) and on day 14 after the intervention or on discharge day. Length of stay in the hospital and length of stay in the ICU were also measured as secondary outcomes of the study.
Results: The results showed a significant decrease in LDH (P=0.01), mean WBC (P=0.04) and length of stay (P=0.04) of patients with COVID-19 in the group treated with Famotidine compared to the control group. There was also a significant increase in oxygen saturation (P=0.01) in the group treated with Famotidine compared to the control group. Cough improvement was also higher in the oral Famotidine group compared to the control group (P=0.02).
Conclusion: This was the first clinical trial on the effect of Famotidine on the improvement of hospitalized COVID-19 patients, which indicated that high-dose Famotidine improves patients’ clinical signs and reduces the severity of the disease and duration of hospitalization.

Keywords: Famotidine, COVID-19, Hospitalization

Full-Text [PDF 497 kb] (577 Downloads)

Type of Study: orginal article | Subject: Special

References

1. Malone RW, Tisdall P, Fremont-Smith P, Liu Y, Huang XP, White KM, et al. COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms. Front Pharmacol 2021;12:633680. [DOI:10.3389/fphar.2021.633680] [PMID] [PMCID]

2. Janowitz T, Gablenz E, Pattinson D, Wang TC, Conigliaro J, Tracey K, et al. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut 2020;69(9):1592-7. [DOI:10.1136/gutjnl-2020-321852] [PMID] [PMCID]

3. Freedberg DE, Conigliaro J, Wang TC, Tracey KJ, Callahan MV, Abrams JA, et al. Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study. Gastroenterology 2020;159(3):1129-31. [DOI:10.1053/j.gastro.2020.05.053] [PMID] [PMCID]

4. Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B 2020;10(5):766-88. [DOI:10.1016/j.apsb.2020.02.008] [PMID] [PMCID]

5. Sen Gupta PS, Biswal S, Singha D, Rana MK. Binding insight of clinically oriented drug famotidine with the identified potential target of SARS-CoV-2. J Biomol Struct Dyn 2021;39(14):5327-33. [DOI:10.1080/07391102.2020.1784795] [PMID]

6. Shaffer L. 15 drugs being tested to treat COVID-19 and how they would work. Nat Med [Internet]. 2020 May 15; Available from: https://pubmed.ncbi.nlm.nih.gov/32415251/ [DOI:10.1038/d41591-020-00019-9]

7. Samimagham HR, Hassani Azad M, Haddad M, Arabi M, Hooshyar D, KazemiJahromi M. The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial. Trials 2020;21(1):1-3. [DOI:10.1186/s13063-020-04773-6] [PMID] [PMCID]

8. Hu Y, Jin Y, Han D, Zhang G, Cao S, Xie J, et al. Mast Cell-Induced Lung Injury in Mice Infected with H5N1 Influenza Virus. J Virol 2012;86(6):3347-56. [DOI:10.1128/JVI.06053-11] [PMID] [PMCID]

9. Marshall JS, Portales-Cervantes L, Leong E. Mast Cell Responses to Viruses and Pathogen Products. Int J Mol Sci 2019;20(17):4241. [DOI:10.3390/ijms20174241] [PMID] [PMCID]

10. Thangam EB, Jemima EA, Singh H, Baig MS, Khan M, Mathias CB, et al. The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: The hunt for new therapeutic targets. Front Immunol 2018;9:1873. [DOI:10.3389/fimmu.2018.01873] [PMID] [PMCID]

11. Hogan RB, Hogan RB, Cannon T, Rappi M, Studdard J, Paul D, et al. Dual-Histamine Blockade with Cetirizine - Famotidine Reduces Pulmonary Symptoms in COVID-19 Patients. Pulm Pharmacol Ther 2020; 63:101942 [DOI:10.1016/j.pupt.2020.101942] [PMID] [PMCID]

12. Loffredo M, Lucero H, Chen DY, O'Connell A, Bergqvist S, Munawar A, et al. The Effect of Famotidine on SARS-CoV-2 Proteases and Virus Replication [Internet]. bioRxiv; 2020 [cited 2022 Jun 29]. p. 2020.07.15.203059. Available from: https://www.biorxiv.org/content/10.1101/2020.07.15.203059v1 [DOI:10.1101/2020.07.15.203059]

13. Ortega JT, Serrano ML, Jastrzebska B. Class A G Protein-Coupled Receptor Antagonist Famotidine as a Therapeutic Alternative against SARS-CoV2: An In Silico Analysis. Biomolecules 2020;10(6):954. [DOI:10.3390/biom10060954] [PMID] [PMCID]

14. Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis. 2020; ciaa270. [PMID] [PMCID]

15. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect 2020;81(2):e16-25. [DOI:10.1016/j.jinf.2020.04.021] [PMID] [PMCID]

16. Zhao D, Yao F, Wang L, Zheng L, Gao Y, Ye J, et al. A Comparative Study on the Clinical Features of Coronavirus 2019 (COVID-19) Pneumonia with Other Pneumonias. Clin Infect Dis. 2020 Jul 28;71(15):756-61. [DOI:10.1093/cid/ciaa247] [PMID] [PMCID]

17. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020 Jul 1;146(1):110-8. [DOI:10.1016/j.jaci.2020.04.006] [PMID] [PMCID]

18. Ji D, Zhang D, Xu J, Chen Z, Yang T, Zhao P, et al. Prediction for Progression Risk in Patients with COVID-19 Pneumonia: The CALL Score. Clin Infect Dis. 2020 Sep 12;71(6):1393-9. [DOI:10.1093/cid/ciaa414] [PMID] [PMCID]